Imiquimod

Imiquimod is an imidazoquinoline agonist of toll-like receptor 7 (TLR7, EC50 = 2.12 µM). It increases TNF-alpha and IL-12 p40 production in IFN-gamma-treated murine peritoneal macrophages in a concentration- and MyD88-dependent manner. Topical application of imiquimod (30 µl of 5% cream) increases TNF and IFN levels at the application site in hairless mice. Imiquimod dose-dependently increases serum levels of IFN-alpha in mice when administered by gavage. It reduces tumor growth in an MC-26 model of murine colon cancer when administered at a dose of 30 mg/kg every three days. Imiquimod (5 mg/kg, intravaginally, twice daily) reduces vaginal viral titer and lesion formation in a guinea pig model of genital HSV-2 infection. Formulations containing imiquimod have been used in the treatment of actinic keratosis, superficial basal cell carcinoma, and external genital warts.Formal Name: 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. CAS Number: 99011-02-6. Synonyms: R-837, S-26308, TMX 101. Molecular Formula: C14H16N4. Formula Weight: 240.3. Purity: >95%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 1 mg/ml, DMSO: 1 mg/ml. lambdamax: 240, 246, 267, 326 nm. SMILES: NC1=NC2=C(C3=C1N=CN3CC(C)C)C=CC=C2. InChi Code: InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17). InChi Key: DOUYETYNHWVLEO-UHFFFAOYSA-N.